uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
uniQure provided a press release today sharing that testing of high-dose AMT-130 in their HD gene therapy study has been suspended for safety reasons due to serious adverse events in some participants. So far the lower dose continues to appear safe and data readouts are still expected in 2023.
